Health Journal Online

Tag: Disease

  • 12 Early Disease Symptoms Most People Ignore That Could Be Serious Health Warning Signs

    12 Early Disease Symptoms Most People Ignore That Could Be Serious Health Warning Signs

    Many serious illnesses begin with subtle early symptoms that people often dismiss as normal stress, aging, or temporary discomfort. These warning signs can appear gradually, making it easy to overlook their significance until the condition has progressed. In today’s fast-paced routines, people tend to push aside physical discomforts, unaware that these minor issues may be the body’s earliest warning signs that something is wrong.

    Recognizing health warning signs early encourages timely medical attention that may prevent complications and improve survival rates. Understanding which symptoms are commonly ignored helps individuals make informed decisions about when to seek evaluation. This article highlights 12 early symptoms that should never be ignored and explains why monitoring these signals can make a crucial difference in long-term health and well-being.

    12 Common Early Symptoms Often Overlooked and Their Health Risks

    People frequently ignore early symptoms that may signal developing diseases, assuming they will resolve on their own. However, these issues often provide important clues about underlying conditions that need medical attention.

    1. Persistent Fatigue: Chronic tiredness that doesn’t improve with rest may indicate anemia, thyroid disorders, diabetes, or chronic infections.
    2. Unexplained Weight Loss: Sudden weight loss without lifestyle changes can signal diabetes, digestive disorders, or various cancers.
    3. Persistent Cough or Hoarseness: A long-lasting cough may reflect asthma, COPD, chronic infections, or early lung cancer.
    4. New or Growing Lumps: Lumps in the breasts, lymph nodes, or other areas may represent infections or early malignancies that require evaluation.
    5. Chest Pain or Pressure: Ignoring chest discomfort can lead to missed signs of angina, heart attack, or vascular disease.
    6. Changes in Bowel Habits: Ongoing diarrhea, constipation, or blood in stool may indicate inflammatory bowel disease or colorectal cancer.
    7. Skin Changes or Non-Healing Wounds: New moles, color changes, or persistent sores can point to skin cancer or systemic illness.
    8. Unexplained Bruising: Frequent or unusual bruising may be linked to blood disorders, vitamin deficiencies, or liver problems.
    9. Persistent Headaches: Recurring or worsening headaches can signal hypertension, neurological conditions, or hormonal imbalances.
    10. Changes in Vision or Hearing: Gradual or sudden sensory changes may signal nerve damage, infections, or chronic diseases such as diabetes.
    11. Shortness of Breath: Difficulty breathing can be an early warning sign of heart disease, respiratory illness, or anemia.
    12. Unusual Pain or Numbness: Pain without clear cause or numbness in limbs may indicate nerve issues, circulation problems, or autoimmune disease.

    Why Do People Ignore Health Warning Signs?

    People often dismiss symptoms due to:

    • Fear of diagnosis: Avoiding medical evaluation to escape bad news.
    • Symptom normalization: Assuming issues like fatigue or pain are “part of getting older.”
    • Busy lifestyles: Prioritizing work or responsibilities over personal health.
    • Lack of awareness: Not understanding that early symptoms may reflect more serious issues.

    Education and awareness greatly influence how people respond to early symptoms and whether they seek help promptly.

    Which Symptoms Indicate Urgent Medical Attention?

    Some symptoms require immediate evaluation because they may signal life-threatening conditions:

    • Sudden chest pain or pressure
    • Severe abdominal pain
    • Difficulty breathing
    • Confusion, fainting, or loss of consciousness
    • Sudden weakness, numbness, or slurred speech

    Recognizing these health warning signs allows for rapid intervention that may prevent permanent damage or death.

    Strategies to Improve Awareness and Response to Early Symptoms

    Improving awareness of health warning signs plays a critical role in early diagnosis. Public health campaigns teach communities about symptoms associated with cancer, cardiovascular disease, and chronic illnesses. These initiatives encourage individuals to monitor changes in their health and seek help when something feels unusual.

    Digital health tools have become increasingly valuable in tracking early symptoms. Smartphone apps can log pain patterns, monitor heart rate, analyze sleep quality, and detect abnormal changes that might otherwise go unnoticed. Routine screenings also help catch diseases that progress silently, such as high blood pressure, diabetes, or early-stage cancer. Meanwhile, healthcare providers guide patients in understanding symptoms, assessing risk factors, and knowing when to seek medical advice. Integrating these strategies builds a more proactive and health-conscious population.

    How to Build Better Habits for Responding to Early Symptoms

    Responding effectively to early symptoms requires consistent and mindful habits. Individuals can start by practicing body awareness, taking note of unusual changes in energy levels, appetite, or physical sensations. Keeping a simple health journal helps track patterns over days or weeks, making it easier to identify persistent symptoms.

    Scheduling regular medical checkups also plays a major role in early detection. Even when symptoms seem minor, discussing them with a healthcare professional provides reassurance or highlights potential concerns. Practicing healthy lifestyle habits—balanced nutrition, sleep hygiene, and stress management—strengthens the body and makes deviations easier to notice. By making health monitoring a routine part of daily life, people become more equipped to respond promptly to early symptoms and prevent serious complications.

    Conclusion

    Early symptoms often appear subtle, and many people assume they are temporary inconveniences rather than signals of disease. However, overlooking these warning signs delays diagnosis and may lead to more severe complications. Understanding the significance of unexplained fatigue, persistent pain, lumps, or changes in bodily functions empowers individuals to respond more thoughtfully to their health.

    By adopting better awareness, using digital tools, and seeking medical guidance when symptoms arise, people can identify disease earlier and improve long-term outcomes. Prioritizing health warning signs strengthens overall well-being and supports a life where issues are addressed promptly instead of becoming emergencies. Recognizing early symptoms is a simple yet powerful step toward preserving health and preventing serious illness.

    Frequently Asked Questions

    1. What are common early symptoms people ignore?

    Fatigue, mild pain, skin changes, odd lumps, unusual bleeding, digestive changes, and cognitive shifts are often dismissed despite being early symptoms of disease.

    2. When should someone seek medical advice for symptoms?

    Symptoms that persist, worsen, or interfere with daily activities—especially those involving breathing, consciousness, or severe pain—require prompt evaluation.

    3. How to differentiate between minor aches and serious symptoms?

    Consider duration, intensity, and additional signs. If unsure, medical assessment is always the safest option.

    4. Can ignoring early symptoms lead to complications?

    Yes. Delays in addressing health warning signs can lead to late diagnoses, advanced disease stages, and serious long-term complications.



    Originally published on Science Times

    Source link

  • State-of-the-art Coronary Artery Disease Treatments

    State-of-the-art Coronary Artery Disease Treatments

    Coronary Artery Disease (CAD) remains a leading cause of death globally, but the treatments are rapidly changing. While traditional methods like lifestyle changes, medications, and surgeries have long been the cornerstone of care, these are now being enhanced by modern innovations. As highlighted by Nishi Patel, recent medical therapies target underlying biological processes, offering new hope to patients previously considered high-risk or untreatable.

    In parallel, imaging tools and minimally invasive techniques are transforming how physicians approach complex cases. Hybrid strategies and emerging technologies like robotics and gene therapy are also expanding the frontiers of what’s possible in cardiac care.

    Coronary Artery Disease and How It Is Traditionally Treated

    Coronary Artery Disease (CAD) develops when the arteries supplying blood to the heart become narrowed or blocked by plaque buildup. This reduces blood flow, which can lead to chest pain, shortness of breath, or even heart attacks. Common contributors include high cholesterol, smoking, high blood pressure, and diabetes.

    Traditional management of CAD focuses on relieving symptoms and preventing further heart damage. Lifestyle changes like improved diet and regular exercise are often combined with medications to control blood pressure and cholesterol. In more advanced cases, procedures such as stent placement or coronary artery bypass surgery are used to restore blood flow.

    Why Traditional Treatments May Not Be Enough

    While stents and bypass surgery have improved outcomes for many with coronary artery disease, they aren’t a universal solution. Some patients have arteries that are too affected, or their overall health may make surgery too risky. In these cases, traditional interventions may offer limited benefits or may even pose greater harm.

    Post-procedure recovery can also be challenging. Patients may deal with complications such as restenosis, where arteries narrow again after treatment. Others might not experience effective symptom relief, particularly if underlying risk factors remain uncontrolled. These limitations have led to a growing demand for more tailored and less invasive strategies. In addition, some individuals may require repeated interventions, increasing the burden on both the patient and the healthcare system.

    Advances in Medical Therapies and Risk Management

    Nishi Patel says that modern treatments emphasize aggressive medical therapy to address the root causes of CAD. Newer medications like PCSK9 inhibitors significantly reduce LDL cholesterol, while SGLT2 inhibitors are now recognized for their protective cardiovascular effects in patients with diabetes. These therapies are reshaping how clinicians manage risk beyond just symptom control.

    Managing lifestyle-related factors remains central. Digital health platforms now assist patients in tracking diet, exercise, and medication adherence. Participation in cardiac rehabilitation programs, both in-person and virtual, has been shown to improve outcomes by reinforcing long-term behavioral changes and reducing repeat cardiac events.

    Innovations in Minimally Invasive Procedures

    In recent years, interventional cardiology has grown with techniques that reduce the need for open-heart surgery. Imaging tools like intravascular ultrasound (IVUS) and optical coherence tomography (OCT) allow physicians to visualize plaque buildup within arteries in real time, leading to more precise placement of stents. These tools are especially useful in identifying vulnerable plaques that might not be visible on standard angiography.

    Chronic Total Occlusion (CTO) interventions, once considered high-risk and technically challenging, are now more successful due to advances in guidewire technology and operator skill. Patients with long-standing blockages who were previously told nothing could be done now have options that offer meaningful symptom relief. Some centers now specialize in these high-complexity cases, showing improved success rates and fewer complications.

    Drug-coated balloons and bioresorbable scaffolds are also gaining traction. These tools aim to restore blood flow without leaving behind permanent implants, reducing potential complications linked to traditional metal stents. The absence of a permanent structure may also lower the risk of late thrombosis, a concern with older implantable devices.

    Combining Techniques for Better Outcomes

    In complex coronary cases, a hybrid approach that blends surgical and catheter-based techniques can offer the best of both worlds. This strategy is often guided by a multidisciplinary heart team, where cardiologists, surgeons, and imaging specialists collaborate to tailor treatment. The combination of expertise allows for more nuanced decisions and improved procedural planning.

    Shared decision-making plays a crucial role in this process. Rather than a one-size-fits-all approach, patients are encouraged to participate in discussions about risks, benefits, and preferences. This model not only improves satisfaction but can also lead to better adherence and clinical success. As patient populations become more diverse, this individualized approach becomes increasingly important.

    Research and Emerging Technologies

    The future of coronary artery disease treatment is being shaped in labs and clinical trial centers around the world. Researchers are exploring gene therapies aimed at promoting vascular healing and reducing inflammation at the molecular level. Other analyses focus on regenerative techniques to repair damaged heart tissue.

    Nishi Patel explains that robotics and artificial intelligence are also making inroads into interventional cardiology. Robotic-assisted procedures offer greater precision and may reduce radiation exposure for patients and operators. AI-driven imaging analysis is beginning to support real-time decision-making in the cath lab. As these technologies progress, they could redefine how procedures are performed and who can benefit from them.

    Source link

  • Diverticular disease done differently | Dietitian Connection

    Diverticular disease done differently | Dietitian Connection


    Diverticular disease is common yet remains one of the most misunderstood areas of gastrointestinal nutrition.

    In this episode, Advanced APD Katherine Healy joins us to unpack the latest evidence and bring clarity to the management of diverticular disease. From acute flare-ups to prevention, Katherine shares how to move beyond outdated advice and deliver patient-centred, evidence-based care.

    Hosted by Bec Sparrowhawk

    Biography

    Katherine Healy is an Advanced Accredited Practising Dietitian with over 14 years’ experience across the full spectrum of gastrointestinal disorders. Beginning her career as a microbiological scientist, she blends her love of science and food to deliver evidence-based, patient-centred care. Her research with Monash University explored enzyme therapy in low FODMAP diets, and she now leads pioneering dietitian-led gastroenterology clinics at Northern Health, transforming how dietitians contribute to GI care.


    In this episode, we discuss:

    • The evolving understanding of diverticular disease and its causes
    • Evidence-based nutrition strategies from flare-up to recovery
    • How to debunk myths around historical nutrition advice
    • Practical communication tools to empower patients

    Additional resources

    Can connect with Katherine via email on [email protected]

    For further reading

     

    The content, products and/or services referred to in this podcast are intended for Health Care Professionals only and are not, and are not intended to be, medical advice, which should be tailored to your individual circumstances. The content is for your information only, and we advise that you exercise your own judgement before deciding to use the information provided. Professional medical advice should be obtained before taking action. The reference to particular products and/or services in this episode does not constitute any form of endorsement. Please see  here  for terms and conditions.


    Source link
  • Gene Therapy for Children With Rare ‘Bubble Boy Disease’ Proves Effective After Long-Term Follow-Up

    Gene Therapy for Children With Rare ‘Bubble Boy Disease’ Proves Effective After Long-Term Follow-Up

    The 62 children who were found to have the rare “Bubble Boy disease” as babies and toddlers between 2012 and 2017 still seem cured after long-term follow-up, after being treated with a genetic therapy for severe combined immunodeficiency.

    The results of the trial noted that by 2019, 95 percent of the children, which equates to all but two of the young patients, showed complete immune system reconstruction. And now, years later, long-term follow-up results show that the therapy is still 95 percent effective.

    Treatment for Children With Rare “Bubble Boy Disease”

    In a statement, a pediatric transplant physician at the University of California, Los Angeles, Donald Kohn, MD, said that the durability of immune function, the consistency over time, and the continued safety profile among the children were all encouraging.

    Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is typically caused by mutations in an individual’s ADA gene. This gene is responsible for creating an enzyme that is essential for a person’s immune function, according to Good News Network.

    For kids who have this rare condition, typical daily activities, such as going to school or playing with friends, can result in dangerous, life-threatening infections. If left untreated, ADA-SCID can even be fatal within an infant’s first two years of life.

    SCID suddenly became well-known in America in 1984 because of “the boy in the bubble,” David Vetter. He received a special spacesuit from NASA that allowed him to leave his total medical isolation and see the world. However, despite this suit, the boy passed away due to an infection when he was 12 years old.

    The researchers who led the multi-center program related to the cured children said that the persistence of healthy immune systems and results of long-term follow-up should be taken as signs that the approach could become a standard treatment for individuals with ADA-SCID, Science Media Centre reported.

    An Effective Approach

    The families whose lives were previously defined by the strict isolation of affected individuals are now able to describe ordinary childhood milestones that they would never have dreamed were possible.

    The gene therapy in question is a treatment that was tested by researchers at UCLA in collaboration with institutions in the United Kingdom. It takes a personalized, cell-based approach to correct an individual’s genetic defect.

    The first step in the process is doctors collecting a child’s hematopoietic stem cells from their bone marrow or blood. Then, a laboratory team uses a modified viral vector to deliver a healthy copy of the ADA gene into those stem cells. Finally, those corrected stem cells are returned to the patient, where they then engraft and produce a continual supply of functional immune cells, as per the Valley Vanguard Online.



    Originally published on parentherald.com

    © {{Year}} ParentHerald.com All rights reserved. Do not reproduce without permission.

    Source link

  • Might Meat Trigger Parkinson’s Disease? 

    Might Meat Trigger Parkinson’s Disease? 

    What does the gut have to do with developing Parkinson’s disease?

    Parkinson’s disease is an ever-worsening neurodegenerative disorder that results in death and affects about 1 in 50 people as they get older. A small minority of cases are genetic, running in families, but 85% to 90% of cases are sporadic, meaning they seem to pop up out of nowhere. Parkinson’s is caused by the death of a certain kind of nerve cell in the brain. Once about 70% of them are gone, the symptoms start. What kills off those cells? It still isn’t completely clear, but the abnormal clumping of a protein called alpha-synuclein or α-synuclein is thought to be involved. Why? Researchers injected blended Parkinson’s brains into the heads of rats and monkeys, and Parkinson’s pathology and symptoms were induced. It can even happen when injecting just the pure, clumped α-synuclein strands themselves. How, though, do these clumps naturally end up in the brain?

    As I discuss in my video The Role Meat May Play in Triggering Parkinson’s Disease, it all seems to start in the gut. The part of the brain where the pathology often first appears is directly connected to the gut, and we have direct evidence of the spread of Parkinson’s pathology from the gastrointestinal (GI) tract to the brain: α-synuclein from brains of Parkinson’s patients is taken up in the gut wall and creeps up the vagal nerves from the gut into the brain—at least that was the case in rats. If only we could go back and look at people’s colons before they got Parkinson’s. Indeed, we can. Old colon biopsies from people who would later develop Parkinson’s were dredged up, and, years before symptoms arose, you could see the α-synuclein in their gut.

    Research supported by the Michael J. Fox Foundation has found that you can reliably distinguish the colons of patients from controls by the presence of this Parkinson’s protein lodged in the gut wall. But how did it get there in the first place? Are “vertebrate food products…a potential source of prion-like α-synuclein”? Indeed, nearly all the animals with backbones that we consume—cows, chickens, pigs, and fish—express the protein α-synuclein. So, when we eat common meat products, when we eat skeletal muscle, we’re eating nerves, blood cells, and the muscle cells themselves. Every pound of meat contains, on average, half a teaspoon of blood, and that alone could be an α-synuclein source to potentially trigger a clumping cascade of our own α-synuclein in the gut. Though “it may seem intuitive that dietary α-synuclein could seed aggregation in the gut,” this kind of buildup, what evidence do we have that it’s actually happening?

    We have some pretty interesting data. There’s a surgical procedure called a vagotomy, in which the big nerve that goes from our gut to our brain—the vagus nerve—is cut as an old-timey treatment for stomach ulcers. Would cutting communication between the gut and the brain reduce Parkinson’s risk? Apparently so, suggesting that the gut to brain’s vagal nerve may be critically involved in the development of Parkinson’s disease.

    Of course, “many people regularly consume meat and dairy products, but only a small fraction of the general population will develop PD,” Parkinson’s disease. So, there must be other factors at play that “may provide an opportunity for unwanted dietary α-synuclein to enter the host, and initiate disease.” For example, our gut becomes leakier as we age, so might that play a role? What else makes our gut leaky? “Dietary fiber deprivation has also been shown to degrade the intestinal barrier and enhance pathogen entry.” So, this raises “possibilities for food-based therapies.”

    Parkinson’s patients have significantly less Prevotella in their gut, a friendly fiber-eating flora that bolsters our intestinal barrier function. So, low levels of Prevotella are linked to a leaky gut, which has been linked to intestinal α-synuclein deposition, but fiber-rich foods may bring Prevotella levels back up. “Therefore, it is possible that by adopting a plant-based diet, in addition to the beneficial effects of phytonutrients, increasing overall fiber intake may modify gut microbiota and gut permeability [leakiness] in beneficial ways for people with PD.”

    So, does a vegan diet—one with lots of fiber and no meat—reduce risk for Parkinson’s? Parkinson’s “appears to be rare in quasi-vegan cultures,” with rates that are about five times lower in rural sub-Saharan Africa, for instance. All this time, we were thinking the benefits seen for Parkinson’s from plant-based diets were due to the antioxidants and anti-inflammatory nature of the animal-free diets, but maybe it’s also due to the increased intestinal exposure to fiber and decreased intestinal exposure to ingested nerves, muscles, and blood.

    Wasn’t that fascinating? For more on Parkinson’s, see the related posts below.



    Source link

  • First Successful Gene Therapy for Huntington’s Disease Slows Disease Progression by 75%

    First Successful Gene Therapy for Huntington’s Disease Slows Disease Progression by 75%

    An experimental gene therapy developed by uniQure has, for the first time, shown a dramatic slowing of Huntington’s disease progression in human patients, offering hope for a condition long considered incurable.

    How the Trial Worked

    The therapy, called AMT-130, was administered via a one-time neurosurgical procedure lasting 12 to 20 hours using a modified viral vector to deliver corrective DNA to regions of the brain affected by the disease. Patients treated with a high dose saw their disease progress 75% more slowly over a 36-month period compared to matched external controls. Secondary outcomes showed a 60% slower decline in functional abilities. The treatment was generally well-tolerated, with no major new safety concerns reported.

    Sarah Tabrizi, director of UCL’s Huntington’s Disease Centre, said these findings mark “We now have a treatment for one of the world’s more terrible diseases. This is absolutely huge. I’m really overjoyed.” uniQure now plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration in early 2026.

    Regulatory Advances & Future Steps

    Earlier in 2025, the FDA granted AMT-130 Breakthrough Therapy designation, which may expedite review and regulatory pathways. In a regulatory update, uniQure disclosed that it is aligning key analytic and manufacturing plans with FDA guidance ahead of the BLA submission.

    The company intends to use external control data sets, like ENROLL-HD, for primary comparisons in its statistical analysis plan.

    Why This Breakthrough Is So Significant

    • Disease-modifying therapy: Until now, Huntington’s treatments have only addressed symptoms; AMT-130 indicates the possibility of altering disease trajectory.
    • One-time administration: Because it is delivered via a single surgical procedure, its benefits—if durable—could last years without repeated dosing.
    • High unmet need: In the U.S., about 41,000 people live with Huntington’s and over 200,000 carry risk alleles.
    • Scientific validation: The magnitude of effect in this trial is among the most convincing in neurodegenerative disease research to date.

    How AMT-130 Compares to Other Gene Therapies

    AMT-130’s approach—one-time neurosurgical delivery of a vector designed to suppress the mutant huntingtin protein—is somewhat unique among genetic therapies, in both delivery method and disease target.

    Here are some points of comparison:

    Therapy Mode of Delivery / Regimen Indication / Age Group Key Strengths Known Limitations / Risks
    AMT-130 (uniQure) Single stereotactic brain surgery (direct striatal infusion) Early-manifest Huntington’s disease Promising stabilization of function, one-time treatment, demonstrable biomarker improvements Surgical risks, inflammatory complications, durable long-term efficacy unknown
    Zolgensma (Onasemnogene abeparvovec-AVXS-101) Single intravenous or intrathecal in some trials Spinal Muscular Atrophy (infants and older children) Has shown dramatic improvements in survival, motor function; among best-known successful gene therapies Very high cost, immune reactions, limited age window, administration logistics
    Nusinersen (Spinraza) Repeated intrathecal injections (ongoing) SMA across age groups Reduces disease burden, extends life, widely used; well-understood safety profile Requires regular dosing, invasiveness, burdens on patients/caregivers, cost

    Cautions and Limitations

    • Not a cure: While the slowing is impressive, it does not reverse the disease or fully stop its course.
    • Surgery risk and cost: The invasive nature and complexity of delivery limit its applicability, especially in less capable surgical settings.
    • Long-term durability unknown: Whether the effect holds beyond three years remains to be seen.
    • Regulatory and access hurdles: Approval does not guarantee access, and pricing, reimbursement, and manufacturing scale remain major challenges.

    Source link

  • Where To Get Huntington’s Disease Treatment? Hope Flows As Doctors Claim First Patient Cured From Neuro Illness

    Where To Get Huntington’s Disease Treatment? Hope Flows As Doctors Claim First Patient Cured From Neuro Illness

    In a groundbreaking development, researchers in the UK have reported the first-ever successful treatment for Huntington’s disease, a hereditary neurodegenerative disorder previously deemed incurable. The experimental gene therapy, known as AMT-130, slowed disease progression by 75% over three years, offering renewed hope to patients and families affected by the condition.

    What Is Huntington’s Disease?

    Huntington’s disease is a progressive neurological disorder caused by a mutation in the HTT gene, leading to the production of a toxic protein that damages brain cells. Symptoms typically manifest in mid-adulthood and include motor dysfunction, cognitive decline, and psychiatric disturbances. The disease is fatal, with patients often succumbing within 15–20 years of symptom onset.

    The Breakthrough Treatment

    Led by Professor Sarah Tabrizi at University College London (UCL), the pioneering clinical trial utilised an innovative gene therapy approach. The treatment involves a one-time surgical procedure lasting up to 20 hours, during which a specially engineered, harmless virus is infused directly into the brain. This virus carries a DNA strand designed to deactivate the mutant huntingtin protein responsible for the disease.

    The results have been nothing short of remarkable. According to a press release from UCL, patients who underwent the treatment experienced a 75% reduction in the expected progression of the disease over a three-year period. Instead of the expected rapid decline, these patients maintained neurological function, effectively gaining years of quality life.

    Expert Insights

    Professor Tabrizi expressed her astonishment at the results, stating, ‘We never in our wildest dreams would have expected a 75% slowing of clinical progression.’ She emphasised that this breakthrough could pave the way for earlier interventions, potentially preventing the onset of symptoms altogether.

    Where to Access Huntington’s Disease Treatment in the UK

    For individuals seeking treatment or support for Huntington’s disease, the UK offers several renowned centres specialising in diagnosis, care, and research:

    • University College London (UCL) Institute of Neurology: A leading research and clinical centre focusing on Huntington’s disease, offering multidisciplinary care and conducting pioneering clinical trials.
    • Cardiff University Huntington’s Disease Centre: A prominent centre dedicated to research and coordination of Huntington’s disease studies across South Wales.
    • Royal Hospital for Neuro-disability: Specialises in providing care and support for patients with complex needs due to Huntington’s disease.
    • Guy’s and St Thomas’ NHS Foundation Trust: Offers follow-up services for individuals diagnosed with Huntington’s disease, including participation in clinical trials.

    These institutions are at the forefront of Huntington’s disease care and research, providing essential services to patients and families affected by the condition.

    Global Implications

    Approximately 6,000 to 10,000 individuals in the UK are affected by Huntington’s disease, with many more at risk due to family history. The success of this gene therapy trial has the potential to revolutionise treatment approaches globally.

    Biotechnology company UniQure plans to seek approval for the therapy in the United States, signalling a new era in the fight against this devastating disorder.

    Looking Ahead

    While gene therapy presents a promising avenue for treatment, the procedure remains complex and expensive. As the medical community continues to assess its long-term efficacy and accessibility, this breakthrough stands as a powerful testament to scientific innovation and its potential to transform lives.

    Originally published on IBTimes UK

    Source link

  • Treating Hashimoto’s Disease (Hypothyroidism) Naturally with Diet 

    Treating Hashimoto’s Disease (Hypothyroidism) Naturally with Diet 

    What were the results of a randomized, double-blind, placebo-controlled trial of a daily half teaspoon of powdered black cumin in Hashimoto’s patients?

    “Autoimmune thyroiditis, also known as Hashimoto’s thyroiditis, is an organ-specific autoimmune disorder,” where our body attacks our own thyroid gland, often leading to hypothyroidism due to destruction and scarring of the gland itself. We know there’s a genetic component, since identical twins are more likely to share the disease than fraternal twins. “However, even with identical twins, the concordance rate was only about 50%, emphasizing that important factors such as the environment play a role in disease pathogenesis.” Indeed, even if your identical twin, who has basically your exact same DNA, has the disease, there’s only like a flip of a coin’s chance you’ll get it. Genes load the gun, but the environment may pull the trigger.

    More than 90 synthetic chemicals were noted to show disruption of hormonal balance or thyroid dysfunction.” However, only a few such ‘pollutants show evidence that they contribute to autoimmune thyroid disease.” These include polyaromatic hydrocarbons. Smokers get a lot of them from cigarettes, but in nonsmokers, exposure comes almost entirely from food, as you can see below and at 1:18 in my video Diet for Hypothyroidism: A Natural Treatment for Hashimoto’s Disease. 

    Polycyclic aromatic hydrocarbons are primarily formed when muscle meats, such as beef, pork, fish, or chicken, are cooked using high-temperature methods, such as grilling. PBBs, polybrominated biphenols, are a type of flame-retardant chemical no longer manufactured in the United States, but are still found in the aquatic food chain. PCBs, polychlorinated biphenols, are used in a number of industrial processes and end up in people’s bodies, again, largely through the consumption of fish, but also eggs and other meats, as seen here and at 1:41 in my video.

    So, one might suspect those eating plant-based diets would have lower rates of hypothyroidism, and, indeed, despite their lower iodine intake, vegan diets tended to be protective. But they’ve never been put to the test in an interventional trial. A modification of the Paleolithic diet has been tried in Hashimoto’s patients, but it didn’t appear to improve thyroid function. What did, though, is Nigella Sativa. That name should sound familiar to anyone who’s read my book How Not to Diet or watched my live Evidence-Based Weight Loss presentation. Nigella Sativa is the scientific name for black cumin, which is just a simple spice that’s also used for a variety of medicinal purposes.

    In one study, Hashimoto’s patients received a half teaspoon of powdered black cumin every day for eight weeks in a randomized, double-blind, placebo-controlled trial. Not only was there a significant reduction in body weight, which is why I profiled it in my book, but the black cumin also significantly reduced the thyroid-stimulating hormone, a sign that thyroid function was improving. It even lowered the level of autoimmune anti-thyroid antibodies, as well as increased blood levels of thyroid hormone T3 in these Hashimoto’s patients. In addition, there was a significant drop in Interleukin 23, a proinflammatory cell signal thought to help promote the autoimmune inflammation of the thyroid, which “further confirms the anti-inflammatory nature of the plant.” And what were the side effects? There was a 17 percent drop in “bad” LDL cholesterol, as shown below and at 3:19 in my video.

    Given the fact that patients with Hashimoto’s may be at particularly high risk of developing heart disease, this is exactly the kind of side effects we’d want. “Considering these health-promoting effects of N. Sativa [black cumin], it can be considered as a therapeutic approach in the management of Hashimoto-related metabolic abnormalities.”

    A similar trial failed to find a benefit, though. Same dose, same time frame, but no significant changes in thyroid function. In contrast with the previous study, though, the study participants were not all Hashimoto’s patients, but rather hypothyroid for any reason, and that may have diluted the results. And it’s possible that telling patients to take the black cumin doses with their thyroid hormone replacement therapy may have interfered with its absorption, which is an issue similar to other foods and drugs, and why patients are normally told to take it on an empty stomach. Since there are no downsides—it’s just a simple spice—I figure, why not give it a try? The worst that can happen is you’ll have tastier food.

    Doctor’s Note:

    I get a lot of questions about thyroid function, and I am glad to have been able to do this series. If you missed any of the other videos, see the related posts below.

    For more on black cumin, see my book How Not to Diet and my presentation Evidence-Based Weight Loss. 



    Source link

  • Eating to Treat Crohn’s Disease 

    Eating to Treat Crohn’s Disease 

    Switching to a plant-based diet has been shown to achieve far better outcomes than those reported on conventional treatments for both active and quiescent stages of Crohn’s disease (CD) and ulcerative colitis.

    Important to our understanding and the prevention of the global increase of inflammatory bowel disease (IBD), we know that “dietary fiber reduces risk, whereas dietary fat, animal protein, and sugar increase it.” “Despite the recognition of westernization of lifestyle as a major driver of the growing incidence of IBD, no countermeasures against such lifestyle changes have been recommended, except that patients with Crohn’s disease should not smoke.”

    We know that “consuming whole, plant-based foods is synonymous with an anti-inflammatory diet.” Lists of foods with inflammatory effects and anti-inflammatory effects are shown here and at 0:50 in my video, The Best Diet for Crohn’s Disease.

    How about putting a plant-based diet to the test?

    Cutting down on red and processed meats didn’t work, but what about cutting down on all meat? A 25-year-old man “with newly diagnosed CD…failed to enter clinical remission despite standard medical therapy. After switching to a diet based exclusively on grains, legumes [beans, split peas, chickpeas, and lentils], vegetables, and fruits, he entered clinical remission without need for medication and showed no signs of CD on follow-up colonoscopy.”

    It’s worth delving into some of the details. The conventional treatment he was started on is infliximab, sold as REMICADE®, which can cause a stroke and may increase our chances of getting lymphoma or other cancers. (It also costs $35,000 a year.) It may not even work in 35 to 40 percent of patients, and that seemed to be the case with the 25-year-old man. So, his dose was increased after 37 weeks, but he was still suffering after two years on the drug. Then he completely eliminated animal products and processed foods from his diet and finally experienced a complete resolution of his symptoms.

    “Prior to this, his diet had been the typical American diet, consisting of meat, dairy products, refined grains, processed foods, and modest amounts of vegetables and fruits. Having experienced complete clinical remission for the first time since his Crohn’s disease diagnosis, the patient decided to switch to a whole food, plant-based diet permanently, severely reducing his intake of processed foods and limiting animal products to one serving, or less, per week.” Whenever his diet slipped, his symptoms started coming back, but he could always eliminate them by eating healthier again. After six months adhering to these diet and lifestyle changes, including stress relief and exercise, a follow-up “demonstrated complete mucosal healing [of the gut lining] with no visible evidence of Crohn’s disease.”

    We know that “a diet consisting of whole grains, legumes, fruits, and vegetables has been shown to be helpful in the prevention and treatment of heart disease, obesity, diabetes, hypertension, gallbladder disease, rheumatoid arthritis, and many cancers. Although further research is required, this case report suggests that Crohn’s disease might be added to this list of conditions.” That further research has already been done! About 20 patients with Crohn’s disease were placed on a semi-vegetarian diet—no more than half a serving of fish once a week and half a serving of meat once every two weeks—and they achieved a 100 percent remission rate at one year and 90 percent at two years.

    Some strayed from the diet, though. What happened to them? As you can see below and at 3:32 in my video, after one year, half had relapsed, and, at year two, only 20 percent had remained in remission. But those who stuck with the semi-veg diet had remarkable success. It was a small study with no formal control group, but it represents the best-reported result in Crohn’s relapse prevention published in the medical literature to date. 

    Nowadays, Crohn’s patients are often treated with so-called biologic drugs, expensive injected antibodies that suppress the immune system. They have effectively induced and maintained remission in Crohn’s disease, but not in everybody. The current remission rate in Crohn’s with early use of REMICADE® is 64 percent. So, 30 to 40 percent of patients “are likely to experience a disabling disease course even after their first treatment.” What about adding a plant-based diet? Remission rates jumped up to 100 percent for those who didn’t have to drop out due to drug side effects. Even after excluding milder cases, researchers found that 100 percent of those with serious, even “severe/fulminant disease, achieved remission.”

    If we look at gold standard systematic reviews, they conclude that the effects of dietary interventions on inflammatory bowel diseases—Crohn’s disease and ulcerative colitis—are uncertain. However, this is because only randomized controlled trials were considered. That’s totally understandable, as that is the most rigorous study design. “Nevertheless, people with IBD deserve advice based on the ‘best available evidence’ rather than no advice at all…” And switching to a plant-based diet has been shown to achieve “far better outcomes” than those reported on conventional treatments in both active and quiescent stages in Crohn’s disease and ulcerative colitis. For example, below and at 5:37 in my video, you can see one-year remission rates in Crohn’s disease (100 percent) compared to budesonide, an immunosuppressant corticosteroid drug (30 to 40 percent), a half elemental diet, such as at-home tube feedings (64 percent), the $35,000-a-year drug REMICADE® (46 percent), or the $75,000-a-year drug Humira (57 percent). 

    Safer, cheaper, and more effective. That’s why some researchers have made the “recommendation of plant-based diets for inflammatory bowel disease.”

    It would seem clear that treatment based on addressing the cause of the disease is optimal. Spreading the word about healthier diets could help halt the scourge of inflammatory bowel disease, but how will people hear about this amazing research without some kind of public education campaign? That’s what NutritionFacts.org is all about.

    Doctor’s Note:

    This is the third in a series on inflammatory bowel disease. If you missed the first two, see Preventing Inflammatory Bowel Disease with Diet and The Best Diet for Ulcerative Colitis Treatment.

    My previous Crohn’s videos include Preventing Crohn’s Disease with Diet and Does Nutritional Yeast Trigger Crohn’s Disease?. 



    Source link

  • Living Near This Popular Sports Facility May Triple Your Risk Of Parkinson’s Disease

    Living Near This Popular Sports Facility May Triple Your Risk Of Parkinson’s Disease

    Living next to a golf course may seem like a dream, with lush greens, peaceful surroundings, and an ambience of a luxury lifestyle. However, new research suggests that this idyllic setting could come with a hidden cost. Scientists have found that people living near golf courses may face an increased risk of developing Parkinson’s disease.

    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement and coordination. Common symptoms include tremors, stiffness, slowed movement, and balance problems. While the exact cause is unknown, both genetic and environmental factors are believed to play a role.

    The latest study published in the journal JAMA Network Open reveals that people living within two miles of a golf course face nearly three times the risk of developing Parkinson’s disease. The risk is highest for residents in water service areas where golf courses are located in regions prone to groundwater contamination.

    This heightened risk is linked to the heavy use of pesticides on golf courses, which are applied in the U.S. at rates up to 15 times higher than in many European countries. These chemicals can seep into the soil and contaminate groundwater, raising serious concerns about the safety of local drinking water.

    For the study, researchers analyzed medical records from the Rochester Epidemiology Project, covering 27 counties in Minnesota and Wisconsin between 1991 and 2015. They examined the relationship between living near golf courses and the risk of Parkinson’s disease, focusing on areas surrounding 139 golf courses.

    “We observed that the risk of developing PD was greatest for those living within 1 to 3 miles of a golf course and that the risk of PD generally decreased with increasing distance from a golf course. We also found that individuals getting their drinking water from water service areas with a golf course had nearly double the odds of PD compared with individuals getting drinking water from water service areas without a golf course,” the researchers wrote.

    The researchers found that while the risk of Parkinson’s disease remained steady for those living within three miles of a golf course, it decreased by 13% for every mile beyond that. Pesticides including organophosphates, chlorpyrifos, methylchlorophenoxypropionic acid (MCPP), 2,4-dichlorophenoxyacetic acid (2,4-D), maneb, and organochlorines, which are known to be linked to Parkinson’s disease, are commonly used to treat golf courses.

    Source link